Show simple item record

dc.contributor.authorChen, Fang
dc.contributor.authorJin, Jian-Yue
dc.contributor.authorHui, Timothy S K
dc.contributor.authorJing, Haiman
dc.contributor.authorZhang, Hong
dc.contributor.authorNong, Yaqing
dc.contributor.authorHan, Ying
dc.contributor.authorWang, Weili
dc.contributor.authorMa, Lingyu
dc.contributor.authorYi, Fan
dc.contributor.authorChen, Qingqing
dc.contributor.authorZhang, Yongsheng
dc.contributor.authorFu, Pingfu
dc.contributor.authorYang, Li
dc.contributor.authorXu, Zhiyuan
dc.contributor.authorKong, Feng-Ming Spring
dc.date.accessioned2022-05-24T12:29:44Z
dc.date.available2022-05-24T12:29:44Z
dc.date.issued2022-04-28
dc.identifier.urihttp://hdl.handle.net/10713/18987
dc.description.abstractA total of 735 patients were eligible. The mean post/preRT PLC ratio was 0.66 (95% CI: 0.64-0.68) and mean EDIC of breast cancer was 1.70Gy (95% CI: 1.64-1.75). Both post/preRT PLC ratio and postRT PLC were significantly correlated with EDIC (P<0.001), with R2 of 0.246. For patients with normal preRT PLC, the post/preRT PLC ratio was better associated with EDIC, and postRT PLC was expressed as PLC preRT × (0.89 - 0.16 × EDIC). For patients with preRT lymphopenia, postRT PLC was better associated with EDIC and it was 1.1 - 0.17 × EDIC. Using binned EDIC as the dose variable, the bootstrap validated NTCPs fit the data nicely with R2 of 0.93, 0.96, and 0.94 for grade-1, grade-2, and grade-3 RIL, respectively. The corresponding EDIC to induce 50% of grade-1, grade-2 and grade-3 RIL was 1.2, 2.1 and 3.7 Gy, respectively.en_US
dc.description.urihttps://doi.org/10.3389/fonc.2022.768956en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relationThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.en_US
dc.relation.ispartofFrontiers in Oncologyen_US
dc.rightsCopyright © 2022 Chen, Jin, Hui, Jing, Zhang, Nong, Han, Wang, Ma, Yi, Chen, Zhang, Fu, Yang, Xu and Kong.en_US
dc.subjectbreast canceren_US
dc.subjecteffective dose to the circulating immune cells (EDIC)en_US
dc.subjectlymphopeniaen_US
dc.subjectprediction modelen_US
dc.subjectradiationen_US
dc.titleRadiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer.en_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fonc.2022.768956
dc.identifier.pmid35600350
dc.source.journaltitleFrontiers in oncology
dc.source.volume12
dc.source.beginpage768956
dc.source.endpage
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record